The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1545
April 23, 2018
View Complete Issue         Table of Contents 2019 
Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia
April 23, 2018 (Issue: 1545)
The FDA has approved deutetrabenazine (Austedo – Teva), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of chorea associated with Huntington's disease and, more recently, for treatment of tardive dyskinesia in adults. It is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia
Article code: 1545a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.